Shanghai's Tigermed Consulting, a clinical-stage CRO, raised $80 million with its IPO on Shenzhen's ChiNext exchange, selling 13.4 million shares, ChinaBio Today reports. The company, founded in 2002, operates 39 offices across China and has inked partnerships with CrownBio, NovaSecta and Medidata Solutions ($MDSO). Report